A plausible biological mechanism is a reason to test a treatment. Whether the treatment helps requires a comparison on the outcome of interest. A 2021 trial of N-acetylcysteine, or NAC, illustrates why improvement during a study should be separated from improvement attributable to the assigned medication.
What did the historical human trial test?
McKetin and colleagues randomized 153 adults with methamphetamine dependence to take-home oral NAC, 2400 mg/day (76 participants), or placebo (77), for 12 weeks. Primary outcomes were self-reported use days over four weeks and weekly methamphetamine-positive oral-fluid samples. Intention-to-treat analyses used imputed missing data.
Mean reductions in use days were 6.8 with NAC and 7.3 with placebo. The group difference was 0.5 days, with a 97.5% confidence interval of −3.4 to 4.3. The oral-fluid difference was also nonsignificant: −2.6 percentage points (97.5% CI, −12.6 to 7.4). Craving, dependence and withdrawal outcomes did not show significant advantages. Adherence was imperfect, and oral-fluid collection differed between groups. The authors cautioned that these results did not exclude benefits in other settings, such as relapse prevention after abstinence.
Why is improvement in the NAC group insufficient?
The question in a placebo-controlled experiment is whether the assigned intervention adds benefit relative to its comparator. If one describes only the improvement in the active group, the comparison that motivated randomization disappears from the account.
This is a general interpretive point, rather than an explanation of why any particular participant improved. Changes during a trial can have several explanations. Assigning them all to the medication requires evidence beyond the fact that medication was provided.
How should the null finding be described?
“No significant difference” and “the treatments are identical” are different statements. The confidence interval describes the uncertainty surrounding an estimated difference. It should remain visible when a conclusion is expressed in everyday language.
It is also important to retain the actual confidence level. Replacing a reported 97.5% interval with the more familiar label “95%” would misstate the analysis even if the numerical endpoints were copied correctly. A scientifically careful summary preserves the interval, unit and outcome together.
Does a glutamate rationale establish clinical benefit?
The supplied 2025 McKetin narrative review discusses NAC among pharmacotherapies directed at the cystine/glutamate exchange system and describes disappointing clinical results. That review supplies a research context; the randomized trial supplies the direct comparison summarized here.
Mechanistic reasoning and clinical testing have complementary roles. A proposed pathway can guide the choice of an intervention or endpoint. It cannot substitute for the result of the experiment designed to test that intervention. Conversely, a negative trial should be scoped to what was actually tested rather than expanded into a claim that all research on the pathway is futile.
What belongs in a useful evidence summary?
Identify the population, regimen, comparator, measured outcomes and missing-data approach. Report the between-group finding before offering an explanation. Distinguish a hypothesis for future study from an observed treatment effect. This preserves the contribution of negative evidence without overstating its reach.
Scientific sources
McKetin R, Dean OM, Turner A, et al. N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial. EClinicalMedicine. 2021;38:101005. Historical randomized human trial. DOI: 10.1016/j.eclinm.2021.101005. Primary full-text record.
McKetin R, Kim JH, Turner A, Berk M. Methamphetamine Pharmacotherapy: A Need to Re-focus on the Complex Neurobiological Changes that Occur Both During and After Methamphetamine Use Disorder. CNS Drugs. 2025;39:1061–1070. Supplied narrative review/current opinion. DOI: 10.1007/s40263-025-01214-3.